Golimumab in unresponsive ulcerative colitis

Elisabeth Lippert, Martina Müller, Claudia Ott University Hospital Regensburg, Department of Internal Medicine I, Regensburg, Germany Abstract: Ulcerative colitis (UC) is a chronic inflammation mainly affecting the colon mucosa. It predominantly occurs in younger patients. Until recently,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lippert E, Müller M, Ott C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/450141bee2da4170ac657202e4618544
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:450141bee2da4170ac657202e4618544
record_format	dspace
spelling	oai:doaj.org-article:450141bee2da4170ac657202e46185442021-12-02T06:55:00ZGolimumab in unresponsive ulcerative colitis1177-5475https://doaj.org/article/450141bee2da4170ac657202e46185442014-05-01T00:00:00Zhttp://www.dovepress.com/golimumab-in-unresponsive-ulcerative-colitis-a17024https://doaj.org/toc/1177-5475 Elisabeth Lippert, Martina Müller, Claudia Ott University Hospital Regensburg, Department of Internal Medicine I, Regensburg, Germany Abstract: Ulcerative colitis (UC) is a chronic inflammation mainly affecting the colon mucosa. It predominantly occurs in younger patients. Until recently, the main goals in the treatment of UC were to temper the symptoms, such as diarrhea, pain, and weight loss, by using mesalazine and steroids. With newer medications, such as immunomodulators (thiopurines) and the biologics providing blockade of tumor necrosis factor (TNF), the goals of the therapy in UC have changed to long-term remission and mucosal healing. The first available anti-TNF therapy in UC included infusion therapy with infliximab every few weeks. In 2012, subcutaneously administered adalimumab gained approval for the treatment of UC in Germany. In patients with a mild disease, therapy with mesalazine, orally or topically, can be sufficient. In patients with moderate to severe disease, therapy with azathioprine or anti-TNF is often required to reach disease control; however, this is only efficient in about two-thirds of patients. Some patients either show no response or a lost response while on treatment. So, further medical options are warranted in the treatment of UC. With golimumab, a new approach in the treatment of mild to moderate UC recently became available in Germany and is a promising new option in the therapy regimen for patients with UC. Keywords: anti-TNF, biological therapy, inflammatory bowel diseaseLippert EMüller MOtt CDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 207-210 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Lippert E Müller M Ott C Golimumab in unresponsive ulcerative colitis
description	Elisabeth Lippert, Martina Müller, Claudia Ott University Hospital Regensburg, Department of Internal Medicine I, Regensburg, Germany Abstract: Ulcerative colitis (UC) is a chronic inflammation mainly affecting the colon mucosa. It predominantly occurs in younger patients. Until recently, the main goals in the treatment of UC were to temper the symptoms, such as diarrhea, pain, and weight loss, by using mesalazine and steroids. With newer medications, such as immunomodulators (thiopurines) and the biologics providing blockade of tumor necrosis factor (TNF), the goals of the therapy in UC have changed to long-term remission and mucosal healing. The first available anti-TNF therapy in UC included infusion therapy with infliximab every few weeks. In 2012, subcutaneously administered adalimumab gained approval for the treatment of UC in Germany. In patients with a mild disease, therapy with mesalazine, orally or topically, can be sufficient. In patients with moderate to severe disease, therapy with azathioprine or anti-TNF is often required to reach disease control; however, this is only efficient in about two-thirds of patients. Some patients either show no response or a lost response while on treatment. So, further medical options are warranted in the treatment of UC. With golimumab, a new approach in the treatment of mild to moderate UC recently became available in Germany and is a promising new option in the therapy regimen for patients with UC. Keywords: anti-TNF, biological therapy, inflammatory bowel disease
format	article
author	Lippert E Müller M Ott C
author_facet	Lippert E Müller M Ott C
author_sort	Lippert E
title	Golimumab in unresponsive ulcerative colitis
title_short	Golimumab in unresponsive ulcerative colitis
title_full	Golimumab in unresponsive ulcerative colitis
title_fullStr	Golimumab in unresponsive ulcerative colitis
title_full_unstemmed	Golimumab in unresponsive ulcerative colitis
title_sort	golimumab in unresponsive ulcerative colitis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/450141bee2da4170ac657202e4618544
work_keys_str_mv	AT lipperte golimumabinunresponsiveulcerativecolitis AT muumlllerm golimumabinunresponsiveulcerativecolitis AT ottc golimumabinunresponsiveulcerativecolitis
_version_	1718399688149827584

Golimumab in unresponsive ulcerative colitis

Ejemplares similares